ArticleFrontiers in oncology2022

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review.

Qian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.